Class summary at a glance.

Every drug in the Vasodilator class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: —combined across class
Total Rx claims: —— unique beneficiaries
Generic mfrs (active): 13across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Nitric Oxide

Brand: GENOSYL · — Part D claims (CY24) · First FDA approval: 1999-12-23

2 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Noxivent 102

— Part D claims (CY24) · First FDA approval: 2018-10-04

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Sodium Nitroprusside

Brand: NIPRIDE RTU · — Part D claims (CY24) · First FDA approval: 2017-03-20

11 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ulspira

— Part D claims (CY24) · First FDA approval: 2023-08-04

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.